London-based Compass Pathways PLC, which has adopted the conventional biotech strategy of modifying naturally existing psilocybin into a patentable drug and taking it through clinical trials. The firm, founded in 2020, boasted a stock market value of $2 billion in November 2021, but its shares since have slumped 80 percent.
Small Pharma, a small Canadian start-up that is modifying the psychedelic DMT to treat depression, recently revealed promising results from a study that failed to excite investors. “These results are extremely promising but they had no effect on the share price, zero,” said Jan…
Original Article (Washington Post):
Executive behind Chatg pt pushes for a new revolution: psychedelics
Artwork Fair Use: 564dude